Could a single dose of esketamine ease IBS symptoms?

NCT ID NCT06788444

Recruiting now Symptom relief Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing whether a single low dose of esketamine, given during a colonoscopy, can reduce symptoms of irritable bowel syndrome (IBS) in adults who also have anxiety or depression. The trial plans to enroll 552 participants and will measure symptom severity and quality of life six weeks after the procedure. The goal is to see if this approach provides meaningful relief for people with IBS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: esketamine
What this could lead to: If it works, this could offer a new way to reduce IBS symptoms for people who also have anxiety or depression.
What could go wrong: This is an early-stage trial with no phase, testing only a single dose. The effect may be small or temporary, and esketamine can cause side effects like dizziness or nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANXIETY DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder irritable bowel syndrome major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IRRITABLE BOWEL SYNDROME

Contacts and locations

Locations

Beijing Tiantan Hospital
RECRUITING

Beijing, Beijing Municipality, 100050, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.